COVID-19: Alglucosidase alfa
Alglucosidase alfa has been funded since December 2016 for patients with infantile Pompe disease, subject to Special Authority criteria.
Page updated: 9 April 2020
Renewal of Special Authority
We have removed the requirement for a metabolic physician to apply for renewals of the Special Authority to fund alglucosidase alfa.
Any relevant physician can apply to renew the Special Authority.
Section H of the Pharmaceutical Schedule will also be amended to reflect this change.
Changes are temporary
We intend change the criteria back to the current status once health services have stabilised to a point where it becomes practical to reinstate them.
Who to contact
If you have any questions about this change, email email@example.com
Last updated: 15 April 2020